Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.21 USD | -7.10% | -12.62% | +12.20% |
May. 13 | Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 10.56M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -36M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-11.2
x | P/E ratio 2025 * |
-10.5
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
1 day | -7.10% | ||
1 week | -12.62% | ||
Current month | -12.62% | ||
1 month | -11.14% | ||
3 months | +73.64% | ||
6 months | -19.73% | ||
Current year | +12.20% |
Managers | Title | Age | Since |
---|---|---|---|
Garry Neil
CEO | Chief Executive Officer | 70 | 20-01-31 |
Director of Finance/CFO | 40 | 17-12-31 | |
Dino Miano
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
June Almenoff
BRD | Director/Board Member | 67 | 21-11-09 |
Gilla Kaplan
BRD | Director/Board Member | 76 | 20-10-11 |
Garry Neil
CEO | Chief Executive Officer | 70 | 20-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 10.21 | -7.10% | 11,122 |
24-06-06 | 10.99 | -0.18% | 17,959 |
24-06-05 | 11.01 | +0.09% | 11,326 |
24-06-04 | 11 | -3.93% | 9,984 |
24-06-03 | 11.45 | -2.01% | 15,506 |
Delayed Quote Nasdaq, June 07, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.20% | 10.56M | |
+51.85% | 57.87B | |
+41.82% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- AVTX Stock